137 related articles for article (PubMed ID: 7726498)
1. Pharmacokinetics and dose proportionality of ceftibuten in men.
Lin C; Lim J; Radwanski E; Marco A; Affrime M
Antimicrob Agents Chemother; 1995 Feb; 39(2):359-61. PubMed ID: 7726498
[TBL] [Abstract][Full Text] [Related]
2. Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers.
Lin C; Radwanski E; Affrime M; Cayen MN
Antimicrob Agents Chemother; 1995 Feb; 39(2):356-8. PubMed ID: 7726497
[TBL] [Abstract][Full Text] [Related]
3. Multiple-dose pharmacokinetics of ceftibuten after oral administration to healthy volunteers.
Bressolle F; Galtier M; Kinowski JM; Goncalves F; Edno L; Panis R; Gomeni R
J Pharm Sci; 1994 Sep; 83(9):1236-40. PubMed ID: 7830237
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ceftibuten in children.
Barr WH; Affrime M; Lin CC; Batra V
Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S93-101. PubMed ID: 7567317
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of ceftibuten in humans.
Barr WH; Lin CC; Radwanski E; Lim J; Symchowicz S; Affrime M
Diagn Microbiol Infect Dis; 1991; 14(1):93-100. PubMed ID: 2013216
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double- strength liquid or with ranitidine.
Radwanski E; Nomeir A; Cutler D; Affrime M; Lin CC
Am J Ther; 1998 Mar; 5(2):67-72. PubMed ID: 10099040
[TBL] [Abstract][Full Text] [Related]
7. A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects.
Hernández-Mitre MP; Wallis SC; Morgan EE; Dudley MN; Loutit JS; Griffith DC; Roberts JA
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0109923. PubMed ID: 38059635
[TBL] [Abstract][Full Text] [Related]
8. Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.
Kearns GL; Young RA
Clin Pharmacokinet; 1994 Mar; 26(3):169-89. PubMed ID: 8194281
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
Nix DE; Symonds WT; Hyatt JM; Wilton JH; Teal MA; Reidenberg P; Affrime MB
Pharmacotherapy; 1997; 17(1):121-5. PubMed ID: 9017772
[TBL] [Abstract][Full Text] [Related]
10. Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children.
Kearns GL; Reed MD; Jacobs RF; Ardite M; Yogev RD; Blumer JL
Antimicrob Agents Chemother; 1991 Oct; 35(10):2078-84. PubMed ID: 1759830
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue penetration of ceftibuten.
Wise R; Nye K; O'Neill P; Wostenholme M; Andrews JM
Antimicrob Agents Chemother; 1990 Jun; 34(6):1053-5. PubMed ID: 2393265
[TBL] [Abstract][Full Text] [Related]
12. Failure of ceftibuten to alter single dose theophylline clearance.
Bachmann K; Schwartz J; Jauregui L; Martin M; Nunlee M
J Clin Pharmacol; 1990 May; 30(5):444-8. PubMed ID: 2347955
[TBL] [Abstract][Full Text] [Related]
13. Multiple-Dose Pharmacokinetics of Ceftibuten in Healthy Adults and Geriatric Volunteers.
Radwanski E; Teal M; Affrime M; Cayen M; Lin CC
Am J Ther; 1994 Jun; 1(1):42-48. PubMed ID: 11835066
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency.
Kelloway JS; Awni WM; Lin CC; Lim J; Affrime MB; Keane WF; Matzke GR; Halstenson CE
Antimicrob Agents Chemother; 1991 Nov; 35(11):2267-74. PubMed ID: 1803999
[TBL] [Abstract][Full Text] [Related]
15. The penetration of ceftibuten into the respiratory tract.
Krumpe P; Lin CC; Radwanski E; Cayen MN; Affrime MB
Chest; 1999 Aug; 116(2):369-74. PubMed ID: 10453864
[TBL] [Abstract][Full Text] [Related]
16. Ceftibuten concentrations in human tonsillar tissue.
Scaglione F; Pintucci JP; Demartini G; Dugnani S
Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):940-3. PubMed ID: 9031878
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.
Lakings DB; Novak E; Friis JM; Lunan CM; Paxton LM
Antimicrob Agents Chemother; 1986 Feb; 29(2):271-7. PubMed ID: 3717932
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of single-dose BMY-28100, a new oral cephalosporin.
Barbhaiya RH; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
Antimicrob Agents Chemother; 1990 Feb; 34(2):202-5. PubMed ID: 2327766
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability of ceftibuten in capsule and suspension forms.
Lin CC; Affrime M; Radwanski E; Lim J; Colucci R; Cayen MN
Clin Ther; 1996; 18(6):1139-49. PubMed ID: 9001830
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
